© 2023 MJH Life Sciences™ and Urology Times. All rights reserved.
Eight months of neoadjuvant hormone therapy prior to radiation therapyappears to offer no significant advantage over the standard of 3 monthsof therapy, at least in low- and intermediate-risk prostate cancer patients.